Annlyse Fanton

Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease

Pierre‐Régis Burgel, I. Durieu, R. Chiron et al. · American Journal of Respiratory and Critical Care Medicine · 2021 · 235 citations

Medicine, Pharmacotherapy, Pulmonary Function Testing +15

Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: First French data

Lucie Amoureux, Julien Bador, Eliane Siébor et al. · Journal of Cystic Fibrosis · 2012 · 78 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +9

The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

Pierre‐Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon et al. · The Lancet Respiratory Medicine · 2024 · 47 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +12

Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis: Results from a French Multicenter Prospective Study

Noémie Coron, Marc Pihet, Émilie Fréalle et al. · Mycopathologia · 2017 · 44 citations

Medicine, Infectious Diseases, Pathology +15

Non‐classic cystic fibrosis associated with D1152H <i>CFTR</i> mutation

Isabelle Fajac, D. Hubert, D Grenet et al. · Clinical Genetics · 2009 · 37 citations

Life Sciences, Genetics, Molecular Genetics +11